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Promoting generic medicines to increase access to essential medicines is relevant to achieve the Millennium
Development Goal (MDGs) and post 2015 goals.
There are several barriers to encouraging wider use of generic medicines in health systems, e.g. the widely-held percep-
tion that low price equals low quality and misalignment of provider and consumer incentives. Overcoming the complex
barriers and other challenges can be re-formulated as a ‘generic medicine evidence-based policy agenda’: (1) What policy
and strategies can increase consumer trust in the quality of all medicines granted market authority including generic
products? (2) Are there differences in prices between branded and unbranded generics? (3) What are synergies between
policies that can enhance promoting of generic medicines effectively?
Evaluating the policies promoting generic medicines will be critical to create evidence that countries can use to
implement policies in their local settings.Background
One third of the population does not have access to essen-
tial medicines and promoting generic medicines to in-
crease access to essential medicines is relevant to achieve
the Millennium Development Goal (MDGs) and post
2015 goals [1]. Generic medicines are generally less expen-
sive than originators. However, they offer the same effi-
cacy, safety and quality as the originator. For the purposes
of market approval, the interchangeability of a generic
medicine and the corresponding original (i.e., ‘innovator’)
product is based on criteria which require that the generic
product have the same amount and type of active pharma-
ceutical ingredient and the same therapeutic effectiveness
as the original product. One of the reasons that generics
are priced lower than originators is that medicines regula-
tory authorities do not ask generic manufacturers to re-
peat the clinical trials of the originator in order to grant
market authorization.
For many important compounds (e.g., including Lipitor®
(atorvastatin; Pfizer), Plavix® (clopidogrel; Sanofi–Aventis/
Bristol-Myers Squibb) and Zyprexa ®(olanzapine; Eli Lilly &
Company)) —patents have already expired or will expire
soon and making them more affordable for many payers,* Correspondence: wak@bu.edu
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of these medicines are used to treat non-communicable
diseases which are already responsible for the majority of
deaths worldwide.
Unfortunately, there are several barriers to encouraging
wider use of generic medicines in health systems. These
barriers are complex and may not be easy to overcome.
One of the most intractable barriers is the intellectual
property/access to medicines narrative, with complex is-
sues involving the link between multinational pharmaceut-
ical company patents and prices, delay of generic medicine
approvals (including "pay for delay"), Trade related aspects
of Intellectual Property Rights (TRIPS), Free Trade Agree-
ments, absence of large insurance schemes promoting gen-
eric medicine use, incompetent medicines regulatory
authorities and the like.
One important barrier is perceptual. In a 2008 experi-
ment, 82 men and women were asked to rate the pain
caused by electric shocks applied to their wrist, before and
after taking a pill. Half the participants read that the pill
was $2.50 per dose- the other half read that it had been
discounted to 10 cents. All pills were placebos. The pills
had a strong placebo effect in both groups but over 80% of
those using the expensive pills reported significant pain re-
lief, compared with around 60% on the cheaper pills [2].
The fact that the strength of a placebo-derived response
was greater when the medicine was perceived as morentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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creased use of generic medicines, “if it’s expensive, it must
be better” or its inverse, “if it’s cheaper, it can’t be good.”
Overcoming these, and other, challenges can be
re-formulated as a ‘generic medicine evidence-based
policy agenda’
1. Increasing consumer trust in the quality of all
approved medicines including generic products
Generic medicines policies include those to promote
competition in the pharmaceutical sector such as
providing rapid market authorization, providing
clinical data for generic medicine companies prior to
patent expiry, and mandated generic prescription or
dispensing. Each of these policies however, depends
on a perception, which must be based in reality that
the generic product is of assured quality. If generics
do not have such credibility, prescribers and end
users will prefer to use the originator product.
Overcoming the perception of “cheaper is not as
good” is possible via public information campaigns
and active promotion by insurance schemes.
However, there is insufficient information on how
much public information campaigns actually change
perception, particularly for low and middle income
countries (LMIC). There is also a scarcity of
information on the impact of insurance schemes’
promotion of generic medicines to beneficiaries in
other than high-income settings.
Further, through increasing transparency of
medicine quality testing, it has been shown that low
price is not equated with low quality. However,
there is a lack of studies in low- resource settings.
What are the best practices of functioning and reli-
able Medicine Regulatory Authorities (MRA) to in-
crease consumer trust in the quality of all approved
medicines including generic products? What are the
best practices of other stakeholders such as physi-
cians and pharmacies to increase consumer trust in
the quality of approved medicines including ge-
nerics? It appears the evidence is lacking to answer
these questions. Policy decisions about changing
stakeholders’ perceptions of medicines quality should
be based on comprehensive evaluations.
2. The “branded generic” conundrum
Branded generics are generic medicines that are sold
under a brand name instead of the non-proprietary
name (e.g. Nurofen® as a brand name instead of ibu-
profen, the non-proprietary name). Many persons
will go to a private retailer, possibly driven by the
same perceptions discussed above. A recent study
has shown that the dominant form of generic con-
sumed in the private sector of many LMICs isbranded generics [3]. However, there is little com-
prehensive information on how prices of unbranded
generic medicines compare with branded generic
medicines. Research by WHO and Health Action
International have shown that branded generics can
often more expensive than INN generics [4]. Is this
context specific? Is it generally true that branded
generic medicines are more expensive than un-
branded medicines? Further analyses of the price,
availability and affordability of branded generics
versus unbranded generics are critical to illuminate
these issues.
3. Synergies between stakeholders and policies
Yadav, Sekhri and Curtis [5] looked at
pharmaceutical supply chains and noted that the
incentives of stakeholders to perform certain
actions (e.g., forecasting demand, raising or
lowering prices) are often misaligned. They
believed that misaligned incentives create effects
such as over-reactions, unnecessary interventions,
second guessing, mistrust, and distorted informa-
tion; all of which can degrade the ability of a supply
chain to match supply and demand.
One could, in theory, apply similar principles to
generic medicines. Each stakeholder in the value
chain (e.g., starting from funder/donors,
pharmaceutical companies-generic and originator,
medicines regulators, medicines procurement au-
thorities, prescribers, dispensers, end users) bears
some of the financial and reputational consequences
of certain risks. We argue that behaviors are “misa-
ligned” all along the pharmaceutical value chain, par-
ticularly when incentives and disincentives exist
between adjacent stakeholders, as illustrated by mis-
alignments among physicians and pharmacists with
regard to wholesale, retail and consumer prices. As
another example, quality regulators may, or may
not, have an incentive to expedite regulatory ap-
proval of generics if they need to invest in more cap-
acity or resources to do that [5]. Generic
manufacturers need to be assured of higher volumes
if they reduce wholesale prices.
Experience from high-income countries suggests
that aligning the interests of different users and con-
sumers of generics are necessary when selecting pol-
icy options. These options include: prescribing by
generic name, generic substitution, financial incen-
tives for pharmacy and medicines outlet personnel
to sell low price generic medicines and continued
education of consumers about generic medicines.
However, many of these existing policies require in-
surance schemes to provide incentives to agents
such as physicians or pharmacies to prescribe and
dispense generic medicines.
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What policies should be given priority to promote gen-
eric medicines use in countries that do not have insur-
ance systems that coverage a large proportion of the
population? What policies can incentivize medicine dis-
pensers to provide generic medicines in the absence of
insurance schemes? Unfortunately, there is a paucity of
relevant impact evaluations of pro-generic policies in
LMICs [6]. For instance, various countries in the Asia
Pacific region are attempting to co-ordinate implementa-
tion of generic medicines policies including procurement,
re-imbursement, retail price controls, reference pricing
and alignment of financial incentives among prescribers,
dispensers and consumers to support the uptake of low-
priced generic medicines. Evaluating these policies will be
important to create evidence that other countries can use
to implement policies in their local settings.
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